Breast Cancer Subtypes Based on ER/PR /Her2 Expression:Comparison of Clinicopathologic Features and Survival
Publish place: 12th International Congress on Breast Cancer
Publish Year: 1394
نوع سند: مقاله کنفرانسی
زبان: English
View: 457
نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد
- Certificate
- من نویسنده این مقاله هستم
این Paper در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
ICBCMED12_011
تاریخ نمایه سازی: 2 تیر 1397
Abstract:
Introduction & Aim: Breast cancer is categorized into at least five main groups based on the antibody markers such as ER, PR and HER2 that differ in terms of risk factors,distribution, prognosis, treatment and clinical outcome. Thus we evaluate the breast cancer survival and therapeutic outcomes based on immunohistochemical biomarkers tohighlight the results for better prognosis for eliminating worries among women.Methods: Subjected were 1772 women with new cases of breast cancer diagnosed fromJanuary 1999 to January 2014 at Shohada educational hospital, Tehran. In this study, we selected a simple classification based on the expressions of estrogen, progesteronereceptors and human epidermal growth factor receptor 2 (Her2). We therefore classified breast cancer cases into four subgroups: luminal A ER+ and/or PR+, HER2-); luminal B (ER+ and/or PR+, HER2+); BCL (ER-,PR-, HER2-) and Her2/neu (ER-,PR-, HER2+). P value ≤0.05 was considered as statistically significant. Results: The majority of cases were luminal A (37/16%), followed by the luminal B (15/14%) and (13/12%) BCL whereas only 6/82% of tumors were classified as Her2/neu and other are missing values. There were significant differences between IHC subgroups with respect to grad (p-value ≤0.001). The hazard ratio (HR) for each group compare to luminal A significantly was higher in Her2/neu (HR=3.5, P<0.001) and luminal B was about 2. It means that Her2/neu risk is 3.5 times than luminal A. Conclusion: These findings indicate that the risk of mortality in each sub-group could be modified by adjusting grade and stage
Authors
Mohammad Hadizadeh
Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Hamid Zaferani Arani
Young Researchers and Elite Club, Islamic Azad University, Tehran Medical Sciences Branch, Tehran, Iran